Browsing Tag
Maralixibat
4 posts
Mirum Pharmaceuticals (NASDAQ: MIRM) jumps 13% after VISTAS Phase 2b PSC win
Two Phase 2b wins in seven days. A pre-NDA meeting this summer. Mirum is starting to look less like a single-product rare disease story.
CANbridge doses first patient in phase 2 EMBARK study of CAN108 in BA
CANbridge Pharmaceuticals has dosed the first patient in the phase 2 EMBARK study of CAN108 (maralixibat) in biliary…
Mirum gets FDA breakthrough therapy status for maralixibat for Alagille syndrome
Mirum Pharmaceuticals has secured the breakthrough therapy designation for maralixibat from the US Food and Drug Administration (FDA)…
Mirum Pharmaceuticals raises $120m to advance Maralixibat for rare liver diseases
Mirum Pharmaceuticals, a clinical-stage pharmaceutical company, has successfully raised $120 million in a Series A funding round to…